These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

180 related items for PubMed ID: 20608366

  • 1. [Benefits of tadalafil in sexual activity-related time concerns].
    Yuang RQ.
    Zhonghua Nan Ke Xue; 2010 Jun; 16(6):572-5. PubMed ID: 20608366
    [Abstract] [Full Text] [Related]

  • 2. Therapeutic effectiveness and patient satisfaction after 6 months of treatment with tadalafil, sildenafil, and vardenafil: results from the erectile dysfunction observational study (EDOS).
    Martin-Morales A, Haro JM, Beardsworth A, Bertsch J, Kontodimas S, EDOS Group.
    Eur Urol; 2007 Feb; 51(2):541-50; discussion 550. PubMed ID: 17084518
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Treatment preferences in men with erectile dysfunction: an open label study in Korean men switching from sildenafil citrate to tadalafil.
    Ahn TY, Lee SW, Kim SW, Yang DY, Park NC, Min KS, Park K, Paick JS, Dyachkova Y, Dwight T, Lee MS.
    Asian J Androl; 2007 Nov; 9(6):760-70. PubMed ID: 17968461
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction?
    Doggrell S.
    Int J Impot Res; 2007 Nov; 19(3):281-95. PubMed ID: 17183346
    [Abstract] [Full Text] [Related]

  • 8. Phosphodiesterase type 5 inhibitors' extended duration of response as a variable in the treatment of erectile dysfunction.
    Dunn ME, Althof SE, Perelman MA.
    Int J Impot Res; 2007 Nov; 19(2):119-23. PubMed ID: 16738695
    [Abstract] [Full Text] [Related]

  • 9. Tadalafil and vardenafil vs sildenafil: a review of patient-preference studies.
    Mirone V, Fusco F, Rossi A, Sicuteri R, Montorsi F.
    BJU Int; 2009 May; 103(9):1212-7. PubMed ID: 19154480
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Physician-rated patient preference and patient- and partner-rated preference for tadalafil or sildenafil citrate: results from the Canadian 'Treatment of Erectile Dysfunction' observational study.
    Lee J, Pommerville P, Brock G, Gagnon R, Mehta P, Krisdaphongs M, Chan M, Chan J, Dickson R.
    BJU Int; 2006 Sep; 98(3):623-9. PubMed ID: 16925764
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Phosphodiesterase 5 inhibitors for erectile dysfunction.
    Setter SM, Iltz JL, Fincham JE, Campbell RK, Baker DE.
    Ann Pharmacother; 2005 Sep; 39(7-8):1286-95. PubMed ID: 15941818
    [Abstract] [Full Text] [Related]

  • 17. Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil--review of the literature.
    Gresser U, Gleiter CH.
    Eur J Med Res; 2002 Oct 29; 7(10):435-46. PubMed ID: 12435622
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Co-possession of phosphodiesterase type-5 inhibitors (PDE5-I) with nitrates.
    Chang LL, Ma M, Allmen Hv, Henderson SC, Harper K, Hornbuckle K.
    Curr Med Res Opin; 2010 Jun 29; 26(6):1451-9. PubMed ID: 20394470
    [Abstract] [Full Text] [Related]

  • 20. [Phosphodiesterase inhibitors: effectiveness and new applications].
    van Driel MF.
    Ned Tijdschr Geneeskd; 2006 Jul 22; 150(29):1613-6. PubMed ID: 16901064
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.